The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

FDA Approval, Private Placement Funding Buoy Biotech Firm

  ()
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement.

Analyst Says Pharma Co. 'Meaningfully Undervalued'

Research Report
  ()
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.

Animal Feed Company Evaluating Strategic Alternatives

  ()
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit.

Biopharma Co. Ceases Program to Optimize Resources

Research Report
  ()
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report.

Pharmaceutical Company Sets Gold Standard for New Drugs

  ()
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.

As Countries Bolster Defense, Opportunities Emerge

  ()
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability.

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial

  ()
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill.

Oncology Co. Receives Buy Rating for New Drug Trials

Research Report
  ()
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report.

Trial Results of New Pneumococcal Vaccine Compelling

Research Report
  ()
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report.

Biotech Rated Outperform Advances Top Drug Candidate

Research Report
  ()
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report.

Biotech Co. Set To Reach New Highs

  ()
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.

Phase 3 Trial in Progress of New Ichthyosis Treatment

Research Report
  ()
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report.

Phase 2b Trial of New Drug for Ovarian Cancer Starts

Research Report
  ()
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report.

Biotech Co. Will 'Not Look Back' From Here

Contributed Opinion
  ()
In light of its recent development of a productthat purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp.

Safety Data From One Trial of New Drug Helpful to Another

Research Report
  ()
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report.

Target Price on Texas-Based Drug Co. Implies 1,929% ROI

Research Report
  ()
This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report.

Resverlogix Testing Cure for Covid, the Terrible Spike Protein and Heart Issues

Contributed Opinion
  ()
In light of Resverlogix Corp.'s testing of a cure for long Covid, Bob Moriarty of 321gold.com reviews the company to tell you why he believes it may be a Buy.

New Treatment for Ovarian Cancer Shows Promise

Research Report
  ()
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report.

Coverage Launched on Drug Co. With 140% Upside

Research Report
  ()
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report.

Trial of New Ophthalmic Drug Now Enrolled

Research Report
  ()
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report.

FDA Approval of New Gout Drug Likely, Analyst Says

Research Report
  ()
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report.

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board

  ()
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.

Coverage Launched on Canadian Specialty Pharma Co.

Research Report
  ()
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report.

New Skin Gene Therapy Gets PDUFA Date

Research Report
  ()
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report.

Novel Therapy Corp Captures More of US Licensing Market, First EU Segment

  ()
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream.

Showing Results: 1 to 25 of 39 Next